1.	Stem Cell Transplant for Hematological Malignancy Phase: Phase III Type: Treatment Status: Active Age: 54 and under Sponsor: Other Protocol IDs: 0107M05202, MT2001-02, NCT00176930
2.	Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: NCI Protocol IDs: CBMTG-0601, NCT00438958
3.	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
4.	Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101) Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: NCI, Other Protocol IDs: 715, 2U10HL069294-11, NCT01597778
5.	Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: 95-024, P30CA008748, MSKCC-95024, NCI-V95-0685, NCT00002663
6.	Radiolabeled Monoclonal Antibody Therapy in Treating Adult Patients Who Have Recurrent Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-97-C-0110, NCT00019305
7.	Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 65 and under Sponsor: NCI, Other Protocol IDs: 1409.00, NCI-2010-00130, P01CA078902, FHCRC-1409.00, 4903, NCI-G00-1776, NCT00005803
8.	Stem Cell Transplant for Hematologic Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 8713-HIMSUM, NCT00058825
9.	Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: NCI, Other Protocol IDs: CDR0000447204, P30CA016058, OHSU-HEM-05011-L, OHSU-210, NCT00245037
10.	Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: TNX-650.101, NCT00441818
11.	Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: J0703, NA00005743, NCT00484874
12.	Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 69 Sponsor: NCI Protocol IDs: 070195, 07-C-0195, NCI-07-C-0195, NCT00520130
13.	Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
14.	A-dmDT390-bisFv (UCHT1) Immunotoxin Therapy for Patients With T-cell Diseases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FDA IND 100712, NCT00611208
15.	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer Phase: Phase II, Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, FHCRC-2230.00, IR-6771, NCT00789776
16.	Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 0711003269, NCT00785798
17.	Autologous and Allogeneic Transplant for Relapsed Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 30 and under Sponsor: Other Protocol IDs: AAAA5185, CHNY-01-501, NCT00802113
18.	Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MC0886, NCI-2009-00934, 08-004746, CLBH589BUS17T, NCT00918333
19.	Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 74 Sponsor: NCI Protocol IDs: 080051, 08-C-0051, NCT00923910
20.	Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12-0132, NCT00943319
21.	Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-01456, 09-443-A, CDR0000666432, N01CM00071, UCCRC-09-443-A, 8309, NCT01076543
22.	Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MC0981, NCI-2010-00235, 09-003801, RV-NHL-HL-PI-0466, CRAD001NUS113T, NCT01075321
23.	Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: PSOC 2502, NCI-2010-00907, NCT01165112
24.	Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2010-0065, NCT01169636
25.	Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CC-223-ST-001, NCT01177397